Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners

Simply Wall St.03-02

Arrowhead Pharmaceuticals (ARWR) is back in focus as investors react to progress in its RNA interference drug pipeline, including two therapies in Phase 3 trials and multiple partnerships with large ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616875159?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-02 01:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616875159","market":"hk","top_or_hot":-1,"title":"Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners","media":"Simply Wall St.","content":"<div>\n<p>Arrowhead Pharmaceuticals (ARWR) is back in focus as investors react to progress in its RNA interference drug pipeline, including two therapies in Phase 3 trials and multiple partnerships with large ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/assessing-arrowhead-pharmaceuticals-arwr-valuation-as-its-rn\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 01:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/assessing-arrowhead-pharmaceuticals-arwr-valuation-as-its-rn><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arrowhead Pharmaceuticals (ARWR) is back in focus as investors react to progress in its RNA interference drug pipeline, including two therapies in Phase 3 trials and multiple partnerships with large ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/assessing-arrowhead-pharmaceuticals-arwr-valuation-as-its-rn\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/assessing-arrowhead-pharmaceuticals-arwr-valuation-as-its-rn","article_id":"2616875159","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/assessing-arrowhead-pharmaceuticals-arwr-valuation-as-its-rn","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616875159","pubTimestamp":1772385559,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arrowhead Pharmaceuticals (ARWR) is back in focus as investors react to progress in its RNA interference drug pipeline, including two therapies in Phase 3 trials and multiple partnerships with large pharmaceutical partners.\nSee our latest analysis for Arrowhead Pharmaceuticals.\nThe recent excitement around Arrowhead’s RNAi pipeline and partnerships comes after a choppy few weeks for the stock, with a 1 month share price return of an 8.74% decline but a 90 day share price return of 12.48%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","ARWR":"Arrowhead Research Corporation","BK4588":"碎股"},"translate_title":"随着Arrowhead Pharmaceuticals(ARWR)的RNAi管道与大型制药合作伙伴一起进入第三阶段，评估其估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1.5},"content_text":"Arrowhead Pharmaceuticals (ARWR) is back in focus as investors react to progress in its RNA interference drug pipeline, including two therapies in Phase 3 trials and multiple partnerships with large pharmaceutical partners. See our latest analysis for Arrowhead Pharmaceuticals. The recent excitement around Arrowhead’s RNAi pipeline and partnerships comes after a choppy few weeks for the stock, with a 1 month share price return of an 8.74% decline but a 90 day share price return of 12.48%. Over a longer window, momentum looks stronger, with a 1 year total shareholder return of 234.58% and a 3 year total shareholder return of 95.58%, even though the 5 year total shareholder return of an 8.30% decline shows earlier investors have not had a smooth ride. If this biotech story has your attention, it could be a good moment to scan other potential RNA and genomics peers through our screener of 27 healthcare AI stocks and see what stands out next. With Arrowhead trading at US$63.27, some investors will point to its intrinsic value estimate and analyst targets as signs of a discount, while others may wonder if the recent gains mean the market is already pricing in future growth. AdvertisementMost Popular Narrative: 1.3% Undervalued Arrowhead’s latest fair value narrative points to a price of $64.08, only slightly above the last close at $63.27, which keeps attention firmly on the assumptions behind that number.  Progress in RNAi delivery technology (TRiM platform), pipeline breadth in both prevalent and rare/orphan indications, and first-mover potential in CNS and adipose tissue RNAi expand Arrowhead's competitive edge as advancements in genomics and precision medicine increase the feasibility and personalization of RNAi therapies supporting stronger projected net margins and long-term earnings growth if adoption broadens.  Read the complete narrative. Curious what kind of revenue path and profit margin shift would need to sit behind that fair value, and how a high implied future earnings multiple fits into the story? The most followed narrative lays out a detailed earnings bridge, plus the discount rate used to pull those future cash flows back to today, but keeps one core assumption that could make or break the case. Result: Fair Value of $64.08 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story could look different if partnership payments become less predictable, or if late stage trial results and regulatory decisions do not land as expected. Find out about the key risks to this Arrowhead Pharmaceuticals narrative. Another Angle on Valuation That fair value of $64.08 contrasts sharply with how the market is pricing Arrowhead today on earnings. The current P/E sits at 43.8x, versus 21.7x for the US Biotechs industry and a fair ratio of 20.2x. This suggests a rich premium that could matter if sentiment cools. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ARWR P/E Ratio as at Mar 2026Next Steps Does this mix of optimism and caution fit with how you see Arrowhead right now, or not quite? If you want to move quickly and build your own view using the same checklist investors are watching, take a closer look at the 2 key rewards and 1 important warning sign. Looking for more investment ideas? If Arrowhead has sharpened your interest, do not stop here. Use the screener to quickly spot other opportunities that fit the kind of portfolio you want to build.  Focus on value first by checking companies that screen as potential bargains through our list of 46 high quality undervalued stocks that already clear key quality checks. Prioritize staying power by reviewing businesses on the solid balance sheet and fundamentals stocks screener (39 results) that pair financial resilience with fundamentals many investors watch closely. Get ahead of the crowd by scanning the screener containing 24 high quality undiscovered gems where strong underlying metrics have not yet attracted as much attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616875159","isCrawlerRequest":true}